A phase Ib study of the combination of the aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma

Allison Rosenthal, Shaji K Kumar, Craig Hofmeister, Jacob Laubach, Ravi Vij, Amylou Dueck, Katherine Gano, Alexander Keith Stewart

Research output: Contribution to journalLetter

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)323-325
Number of pages3
JournalBritish Journal of Haematology
Volume174
Issue number2
DOIs
StatePublished - Jul 1 2016

Keywords

  • Alisertib
  • Aurora kinase
  • Bortezomib
  • Multiple myeloma
  • Relapse

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology

Cite this